{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:35:55Z","timestamp":1793727355307,"version":"4.6.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110777","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:20:03Z","timestamp":1787959203000},"page":"110777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical immunology lessons from failed \u03b1-Synuclein and Tau immunotherapies: A roadmap for combination strategies in Alzheimer's disease"],"prefix":"10.1016","volume":"288","author":[{"given":"Ahmed M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma S.","family":"Eltyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110777_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103639","article-title":"Alzheimer disease: amyloid peptide controversies and challenges of anti-A\u03b2 immunotherapy","volume":"392","author":"Almohmadi","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0010","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14737175.2025.2546868","article-title":"Donanemab for Alzheimer\u2019s disease: from preclinical research to the clinical application","volume":"25","author":"Dodel","year":"2025","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.clim.2026.110777_bb0015","doi-asserted-by":"crossref","first-page":"125806","DOI":"10.1016\/j.jns.2026.125806","article-title":"\u03b1-synuclein monoclonal antibodies in Parkinson\u2019s disease: a failed promise or unmet potential?","volume":"482","author":"Messak","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer\u2019s disease are reminiscent of the amyloid-\u03b2 story","volume":"18","author":"Imbimbo","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.clim.2026.110777_bb0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0030","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","article-title":"The evolving landscape of Alzheimer\u2019s disease therapy: from A\u03b2 to tau","volume":"188","author":"Courade","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.clim.2026.110777_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antib15010001","article-title":"Nanobody therapeutics in Alzheimer\u2019s disease: from molecular mechanisms to translational approaches","volume":"15","author":"Godugu","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.clim.2026.110777_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ana.25246","article-title":"Combined neuropathological pathways account for age-related risk of dementia","volume":"84","author":"Power","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0045","first-page":"804","article-title":"Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline","volume":"140","author":"Boyle","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.clim.2026.110777_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"20","author":"Guo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/iub.2194","article-title":"The good and bad of therapeutic strategies that directly target \u03b1-synuclein","volume":"72","author":"Longhena","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.clim.2026.110777_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2026.103337","article-title":"Vaccination strategies in neurodegenerative Proteinopathies","author":"Tao","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.clim.2026.110777_bb0065","doi-asserted-by":"crossref","first-page":"11161","DOI":"10.1038\/srep11161","article-title":"Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody","volume":"5","author":"Luo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0075","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf304","article-title":"Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free \u03b1-synuclein lowered by >50%","volume":"7","author":"Shering","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.clim.2026.110777_bb0085","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clim.2026.110777_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting \u03b1-Synuclein for Parkinson\u2019s disease","volume":"74","author":"Oh","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.clim.2026.110777_bb0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcph.6103","article-title":"Safety, tolerability, and pharmacokinetics of single doses of Exidavnemab (BAN0805), an anti-\u03b1-Synuclein antibody, in healthy Western, Caucasian, Japanese, and Han Chinese adults","volume":"64","author":"Bostr\u00f6m","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2026.110777_bb0100","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.clim.2026.110777_bb0110","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.clim.2026.110777_bb0115","article-title":"Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer\u2019s disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"16","author":"Cai","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3233\/ADR-230012","article-title":"Safety, tolerability, and pharmacokinetics of Zagotenemab in participants with symptomatic Alzheimer\u2019s disease: a phase I clinical trial","volume":"7","author":"Willis","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of Zagotenemab: results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110777_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13195-026-02047-y","article-title":"Etalanetug (E2814) in dominantly inherited Alzheimer\u2019s disease: an open-label phase 1b\/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment","volume":"18","author":"Andreozzi","year":"2026","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0135","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.14283\/jpad.2024.163","article-title":"Phase 1 studies of the anti-tau monoclonal antibody JNJ-63733657 in healthy participants and participants with Alzheimer\u2019s disease","volume":"11","author":"Galpern","year":"2024","journal-title":"J. Prevent. Alzheimer\u2019s Disease"},{"key":"10.1016\/j.clim.2026.110777_bb0140","series-title":"NCT04619420 | A Study of JNJ-63733657 in Participants with Early Alzheimer\u2019s Disease","author":"Study Details","year":"2026"},{"issue":"1","key":"10.1016\/j.clim.2026.110777_bb0145","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"6","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.clim.2026.110777_bb0150","series-title":"NCT02579252 | 24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer\u2019s Disease","author":"Study Details","year":"2026"},{"key":"10.1016\/j.clim.2026.110777_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103338","article-title":"A call for better understanding of target engagement in tau antibody development","volume":"27","author":"Bespalov","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.clim.2026.110777_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","article-title":"Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials","volume":"17","author":"Harris","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-Synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.clim.2026.110777_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/rej.2008.0689","article-title":"Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer\u2019s disease","volume":"11","author":"Solomon","year":"2008","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.clim.2026.110777_bb0175","doi-asserted-by":"crossref","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","article-title":"Antibody uptake into neurons occurs primarily via clathrin-dependent Fc\u03b3 receptor endocytosis and is a prerequisite for acute tau protein clearance","volume":"288","author":"Congdon","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110777_bb0180","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau immunotherapies for Alzheimer\u2019s disease and related tauopathies: progress and potential pitfalls","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.clim.2026.110777_bb0185","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0190","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1038\/s41598-023-41382-0","article-title":"Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model","volume":"13","author":"Geerts","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0195","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41593-025-02125-8","article-title":"The Alzheimer\u2019s therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia","volume":"29","author":"Albertini","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1570553","article-title":"\u03b1-Synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies","volume":"19","author":"Padilla-God\u00ednez","year":"2025","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70053","article-title":"Alpha-Synuclein demonstrates varying binding affinities with different tau isoforms","volume":"169","author":"Fischer","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.clim.2026.110777_bb0220","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.1074\/jbc.RA119.012284","article-title":"Structural basis of the interplay between \u03b1-synuclein and tau in regulating pathological amyloid aggregation","volume":"295","author":"Lu","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110777_bb0225","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/acs.biochem.9b00215","article-title":"Tau interacts with the C-terminal region of \u03b1-synuclein, promoting formation of toxic aggregates with distinct molecular conformations","volume":"58","author":"Dasari","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.clim.2026.110777_bb0230","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/1873-3468.70118","article-title":"A\u03b242 promotes the aggregation of \u03b1-synuclein splice isoforms via heterogeneous nucleation","volume":"599","author":"R\u00f6ntgen","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.clim.2026.110777_bb0235","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10571-025-01604-7","article-title":"Amyloid-\u03b2, tau, and \u03b1-synuclein protein interactomes as therapeutic targets in neurodegenerative diseases","volume":"45","author":"Mohan Kumar","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.clim.2026.110777_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400180","article-title":"Tau protein and tauopathies: exploring tau protein\u2013protein and microtubule interactions, cross-interactions and therapeutic strategies","volume":"19","author":"Di Lorenzo","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.clim.2026.110777_bb0245","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jnr.23576","article-title":"Cyclin-dependent kinase 5 targeting prevents \u03b2-amyloid aggregation involving glycogen synthase kinase 3\u03b2 and phosphatases","volume":"93","author":"Castro-Alvarez","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.clim.2026.110777_bb0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5483\/BMBRep.2022.55.7.073","article-title":"Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson\u2019s disease","volume":"55","author":"Yoo","year":"2022","journal-title":"BMB Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5483\/BMBRep.2018.51.6.077","article-title":"Degradation or aggregation: the ramifications of post-translational modifications on tau","volume":"51","author":"Park","year":"2018","journal-title":"BMB Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109617119","article-title":"\u03b1-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity","volume":"119","author":"Ghanem","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12031-026-02518-9","article-title":"Reimagining GSK-3\u03b2 therapeutics in Alzheimer\u2019s disease: from inhibition to activity normalization and targeted degradation","volume":"76","author":"Manni","year":"2026","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0270","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1021\/acs.biochem.1c00434","article-title":"Modulating \u03b1-synuclein liquid\u2013liquid phase separation: published as part of the Biochemistry virtual special issue \u201cProtein Condensates,\u201d","volume":"60","author":"Sawner","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.clim.2026.110777_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151053","article-title":"Liquid-liquid phase separation of tau and \u03b1-synuclein: a new pathway of overlapping neuropathologies","volume":"741","author":"Rodr\u00edguez","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2026.110777_bb0280","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/pro.4025","article-title":"Interplay between tau and \u03b1-synuclein liquid\u2013liquid phase separation","volume":"30","author":"Siegert","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.26711","article-title":"When Alzheimer\u2019s is LATE: why does it matter?","volume":"94","author":"Nelson","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0290","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3233\/JAD-180169","article-title":"TDP-43 and Alzheimer\u2019s disease pathologic subtype in non-amnestic Alzheimer\u2019s disease dementia","volume":"64","author":"Sahoo","year":"2018","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.clim.2026.110777_bb0295","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1038\/s44318-025-00590-2","article-title":"Direct interaction between TDP-43 and Tau promotes their co-condensation, while suppressing tau fibril formation and seeding","volume":"44","author":"Simonetti","year":"2025","journal-title":"EMBO J."},{"key":"10.1016\/j.clim.2026.110777_bb0300","doi-asserted-by":"crossref","first-page":"12380","DOI":"10.3390\/ijms252212380","article-title":"Co-aggregation of TDP-43 with other pathogenic proteins and their co-pathologies in neurodegenerative diseases","volume":"25","author":"Jiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0305","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.4130","article-title":"The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity","volume":"22","author":"Wang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2019.103396","article-title":"TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration","volume":"100","author":"Gao","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00503-x","article-title":"TDP-43 pathology in Alzheimer\u2019s disease","volume":"16","author":"Meneses","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.clim.2026.110777_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/alz70855_105886","article-title":"TDP-43 and APOE: a complex interaction","volume":"21","author":"Abeer","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0325","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.neurol.2025.08.004","article-title":"Tracing neurological diseases in the presymptomatic phase: moving forward a detection panel","volume":"181","author":"Rival","year":"2025","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.clim.2026.110777_bb0330","article-title":"Digital seed amplification assay for TDP-43 aggregate quantification in CSF","author":"Borberg","year":"2025","journal-title":"MedRxiv"},{"key":"10.1016\/j.clim.2026.110777_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107977","article-title":"TDP-43 in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies","volume":"221","author":"Zhou","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.clim.2026.110777_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1671419","article-title":"TDP-43-proteinopathy at the crossroads of Tauopathy: on copathology and current and prospective biomarkers","volume":"19","author":"Nasir","year":"2025","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.clim.2026.110777_bb0350","first-page":"10","article-title":"An anti-tau therapeutic antibody Etalanetug (E2814): a phase 1, first-in-human (FIH) study of single and multiple ascending doses in healthy subjects","author":"Rawal","year":"2025","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.clim.2026.110777_bb0355","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","article-title":"Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics","volume":"294","author":"Yamasaki","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110777_bb0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/cjhr.cjhr_48_25","article-title":"Lecanemab and Donanemab in early Alzheimer\u2019s disease: a systematic review of clinical, biomarker, and safety outcomes","volume":"12","author":"Gupta","year":"2025","journal-title":"CHRISMED J. Health Res."},{"key":"10.1016\/j.clim.2026.110777_bb0365","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0370","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-025-02952-w","article-title":"Alpha-synuclein deposition patterns in Alzheimer\u2019s disease: association with cortical amyloid beta and variable tau load","volume":"150","author":"Neubauer","year":"2025","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clim.2026.110777_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-00886-4","article-title":"Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data","volume":"11","author":"Xiao","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0380","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0385","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41746-025-01572-8","article-title":"Exploratory digital outcome measures of motor sign progression in Parkinson\u2019s disease patients treated with prasinezumab","volume":"8","author":"Taylor","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0390","first-page":"2001","article-title":"Alpha-Synuclein co-pathology in Alzheimer\u2019s disease drives tau accumulation","author":"Struebing","year":"2025","journal-title":"BioRxiv"},{"key":"10.1016\/j.clim.2026.110777_bb0395","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/brain\/awad059","article-title":"Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated","volume":"146","author":"Robinson","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.clim.2026.110777_bb0400","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clim.2026.110777_bb0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0410","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0415","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrneurol.2010.145","article-title":"Cell-to-cell transmission of non-prion protein aggregates","volume":"6","author":"Lee","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0420","doi-asserted-by":"crossref","first-page":"11266","DOI":"10.1038\/s41467-025-66146-4","article-title":"Seed amplification of MSA alpha-synuclein aggregates preserves the biological and structural properties of brain-derived aggregates","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2026.110777_bb0425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40035-025-00490-9","article-title":"Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials","volume":"14","author":"Zhan","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.clim.2026.110777_bb0430","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90633","article-title":"Lost in translation: inconvenient truths on the utility of mouse models in Alzheimer\u2019s disease research","volume":"13","author":"Granzotto","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.clim.2026.110777_bb0435","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nbd.2012.07.018","article-title":"Expression pattern and localization of alpha-synuclein in the human enteric nervous system","volume":"48","author":"B\u00f6ttner","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0440","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.neuron.2024.08.003","article-title":"Gut-induced alpha-Synuclein and tau propagation initiate Parkinson\u2019s and Alzheimer\u2019s disease co-pathology and behavior impairments","volume":"112","author":"Xiang","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.clim.2026.110777_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq6495","article-title":"Biomolecular condensates can both accelerate and suppress aggregation of \u03b1-synuclein","volume":"8","author":"Lipi\u0144ski","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.clim.2026.110777_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1623","article-title":"Tau induces inflammasome activation and microgliosis through acetylating NLRP3","volume":"14","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0455","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1007\/s12035-025-04918-1","article-title":"Decoding NLRP3 inflammasome activation in Alzheimer\u2019s disease: a focus on receptor dynamics","volume":"62","author":"Maurya","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.clim.2026.110777_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1211273","article-title":"Understanding the heterogeneity and spatial brain environment of neurodegenerative diseases through conventional and future methods","volume":"17","author":"Li","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0465","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jnen\/nlz141","article-title":"Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD","volume":"79","author":"Robinson","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.clim.2026.110777_bb0470","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.3390\/ijms26167817","article-title":"Seed amplification assay for \u03b1-Synuclein: diagnostic applications in Synucleinopathies","volume":"26","author":"Giannakis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0475","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12149-024-01972-y","article-title":"Clinical assessment and striatal dopaminergic activity in healthy controls and patients with Parkinson\u2019s disease: a Bayesian approach","volume":"38","author":"Shin","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.clim.2026.110777_bb0480","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1877718X251325124","article-title":"Seeding amplification assay: limitations and insights for enhanced clinical and research applications","volume":"15","author":"Abdi","year":"2025","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2026.110777_bb0490","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110777_bb0495","article-title":"Model organism development and evaluation for late-onset Alzheimer\u2019s disease: MODEL-AD","volume":"6","author":"Oblak","year":"2020","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.clim.2026.110777_bb0500","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","article-title":"Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease","volume":"20","author":"Franzmeier","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.clim.2026.110777_bb0505","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4103\/1673-5374.382231","article-title":"Pathological and physiological functional cross-talks of \u03b1-synuclein and tau in the central nervous system","volume":"19","author":"Jin","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"10","key":"10.1016\/j.clim.2026.110777_bb0510","doi-asserted-by":"crossref","first-page":"100329","DOI":"10.1016\/j.tjpad.2025.100329","article-title":"Identifying synergistic combinations of repurposed treatments for Alzheimer\u2019s disease","volume":"12","author":"Ballard","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13195-025-01895-4","article-title":"Drug repurposing for Alzheimer\u2019s disease: a Delphi consensus and stakeholder consultation","volume":"17","author":"Corbett","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106050","article-title":"Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS\/FTD","volume":"179","author":"Afroz","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00737","article-title":"Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS","volume":"22","author":"Poulin-Bri\u00e8re","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2026.110777_bb0530","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting a-Synuclein for Parkinson\u2019s disease","volume":"74","author":"Jasutkar","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.clim.2026.110777_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202422834","article-title":"Multi-targeting macrocyclic peptides as nanomolar inhibitors of self-and cross-seeded amyloid self-assembly of \u03b1-Synuclein","volume":"64","author":"Hornung","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.clim.2026.110777_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120986","article-title":"Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer\u2019s disease: mechanisms and possible therapeutic interventions","volume":"308","author":"Maitra","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0545","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-Synuclein, and Tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2026.110777_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2026.124578","article-title":"Targeting PARP1-dependent parthanatos in Alzheimer\u2019s disease: mechanisms and therapeutic opportunities","volume":"402","author":"Alameen","year":"2026","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0555","article-title":"Small-molecule in cancer immunotherapy: revolutionizing cancer treatment with transformative, game-changing breakthroughs","volume":"2024","author":"Chattopadhyay","year":"1879","journal-title":"Biochimica et Biophysica Acta (BBA) Rev. Cancer"},{"key":"10.1016\/j.clim.2026.110777_bb0560","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0565","article-title":"Targeted protein degradation with small molecules for cancer immunotherapy","volume":"20","author":"Yang","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0570","first-page":"1263","article-title":"Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species","volume":"127","author":"Scotter","year":"2014","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.clim.2026.110777_bb0575","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/hmg\/ddy066","article-title":"TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity","volume":"27","author":"Leibiger","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.clim.2026.110777_bb0580","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.neuron.2019.05.048","article-title":"Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS\/FTD","volume":"103","author":"Fang","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.clim.2026.110777_bb0585","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s13311-022-01260-5","article-title":"Emerging therapies and novel targets for TDP-43 Proteinopathy in ALS\/FTD","volume":"19","author":"Hayes","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2026.110777_bb0590","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-023-01592-z","article-title":"Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo","volume":"11","author":"Riemenschneider","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.clim.2026.110777_bb0595","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00401-025-02929-9","article-title":"Differences and overlaps in TDP-43 pathology of \u2018pure\u2019 LATE-NC compared to LATE-NC coexisting with Alzheimer\u2019s disease","volume":"150","author":"Tom\u00e9","year":"2025","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clim.2026.110777_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1671419","article-title":"TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers","volume":"19","author":"Nasir","year":"2025","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0605","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0610","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/alz70859_103609","article-title":"Therapeutic potential of INM-901 in mitigating Alzheimer\u2019s disease pathology: insights from a long-term 5xFAD mouse model study","volume":"21","author":"Somvanshi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0620","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2026.110777_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114692","article-title":"Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson\u2019s disease: from pathogenesis to potential therapeutic strategies","volume":"156","author":"Abdelaziz","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2026.110777_bb0630","doi-asserted-by":"crossref","first-page":"997","DOI":"10.15212\/bioi-2023-0022","article-title":"Targeting the CD24-Siglec10 axis: a potential strategy for cancer immunotherapy","volume":"5","author":"Fang","year":"2024","journal-title":"Bio Integr."},{"key":"10.1016\/j.clim.2026.110777_bb0635","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000518664","article-title":"Macrophage-based combination therapies as a new strategy for cancer immunotherapy","volume":"8","author":"Tian","year":"2022","journal-title":"Kidney Diseas."},{"key":"10.1016\/j.clim.2026.110777_bb0640","article-title":"Therapeutic activities of anti-human SIGLEC10 mAb in multiple transgenic mouse AD models","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/alz70859_101773","article-title":"Mice carrying Unmutated human SIGLEC10 gene cluster transgene develop both amyloid plaques and tau neurofilament tangles: a model for late onset Alzheimer\u2019s disease","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0650","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214648","article-title":"CSF \u03b1-Synuclein seed amplification assays and skin immunofluorescence: clinical applications, research opportunities, and knowledge gaps","volume":"106","author":"Coughlin","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110777_bb0655","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/17520363.2.3.305","article-title":"Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective","volume":"2","author":"Amur","year":"2008","journal-title":"Biomark. Med"},{"key":"10.1016\/j.clim.2026.110777_bb0660","doi-asserted-by":"crossref","DOI":"10.1002\/alz.089250","article-title":"The Emory-sage-SGC-JAX TREAT-AD center: target enabling packages for Alzheimer\u2019s disease emerging targets","volume":"20","author":"Leal","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0665","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","article-title":"Immunotherapies targeting amyloid and tau protein in Alzheimer\u2019s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion","volume":"12","author":"Esquer","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.clim.2026.110777_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.clim.2026.110777_bb0675","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2026.110777_bb0680","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-a\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.clim.2026.110777_bb0685","doi-asserted-by":"crossref","first-page":"E2303","DOI":"10.1212\/WNL.0000000000201202","article-title":"CSF biomarkers of Alzheimer disease in patients with concomitant \u03b1-Synuclein pathology","volume":"99","author":"Cousins","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110777_bb0690","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-025-00822-3","article-title":"Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease","volume":"20","author":"Franzmeier","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.clim.2026.110777_bb0695","doi-asserted-by":"crossref","DOI":"10.1002\/alz.085111","article-title":"The Alzheimer\u2019s Tau platform (ATP): a phase 2, combination amyloid and tau therapy clinical trial for early AD","volume":"20","author":"Boxer","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.clim.2026.110777_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100163","article-title":"Challenges and opportunities for novel combination therapies in Alzheimer\u2019s disease: a report from the EU\/US CTAD task force","volume":"12","author":"Angioni","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.clim.2026.110777_bb0705","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/eht407","article-title":"Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges","volume":"35","author":"W.G. on the S. on C.T. for CVD","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clim.2026.110777_bb0710","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/JCMA.0000000000001252","article-title":"A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum","volume":"88","author":"Wu","year":"2025","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.clim.2026.110777_bb0715","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70131","article-title":"Multi-target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations","volume":"13","author":"Hossain","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.clim.2026.110777_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100695","article-title":"The impact of real-world evidence in implementing and optimizing Alzheimer\u2019s disease care","volume":"6","author":"Hampel","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.clim.2026.110777_bb0725","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimer\u2019s Dement J. Alzheimer\u2019s Assoc."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:01:40Z","timestamp":1793725300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":145,"alternative-id":["S1521661626001154"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110777","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical immunology lessons from failed \u03b1-Synuclein and Tau immunotherapies: A roadmap for combination strategies in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110777"}}